What Is JIRE? JPMorgan International Research Enhanced Equity ETF

JIRE is the JPMorgan International Research Enhanced Equity ETF, an actively managed fund from J.P. Morgan Asset Management that invests in developed-market stocks outside North America. It benchmarks to the MSCI EAFE Index, which spans Europe, Japan, the UK, Australia, and other developed economies. The fund holds roughly 230 names and charges a net expense ratio of about 0.24%.

The defining feature is its research-enhanced approach. Rather than tracking the index exactly or making a few concentrated bets, JIRE makes many small over- and under-weights driven by J.P. Morgan's fundamental research. The goal is to edge past the benchmark over time while keeping sector, country, and overall risk close to the index.

Approximate weights as of mid-2026; refresh quarterly from J.P. Morgan Asset Management's fund page. Each ticker links to its individual stock guide in Walnut.

JIRE's portfolio reads like a who's who of large international companies. Top holdings as of mid-2026 include ASML at roughly 3.2%, AstraZeneca near 2.0%, Siemens, Shell, Allianz, Tokyo Electron, Nestle, HSBC, Roche, and BHP, each in the 1.3% to 1.7% range. No single stock dominates, reflecting the strategy of tilting around an index rather than concentrating.

Geographically, the fund leans on Japan, the UK, France, Germany, and Switzerland, closely matching the MSCI EAFE country mix. Sector exposure is spread across financials, industrials, healthcare, technology, and consumer names. Because the tilts are small, the overall shape of the portfolio stays close to the benchmark it aims to beat.

The obvious alternatives to JIRE are plain index funds. IEFA (0.07%), VEA (0.03%), and EFA (0.32%) simply mirror developed-market benchmarks at rock-bottom or low cost, delivering the index return minus a tiny fee. They make no attempt to outperform.

JIRE sits between those and a fully active fund. At 0.24% it costs more than IEFA or VEA but tries to add value through research-driven tilts while keeping risk near the index. For investors who believe modest active management can add up over time, that trade-off may appeal. For those who prefer the cheapest possible exposure, a plain index fund is the simpler route.

JIRE's returns track the broad developed-market cycle closely, since its risk profile stays near the MSCI EAFE index. The research-enhanced tilts aim to add a modest margin of outperformance over full market cycles rather than in any single year, and results depend on how the manager's small bets play out against the benchmark.

As an international fund, JIRE's US-dollar returns also depend heavily on currency moves. A weaker dollar tends to boost reported returns for US investors, while a stronger dollar can drag on them. Broader drivers include European and Japanese economic growth, interest rates abroad, and global sector trends in healthcare, industrials, and financials.

JIRE may fit investors who want core international-equity exposure with a light active tilt and are comfortable paying 0.24% for the chance to beat the index. Its broad diversification across roughly 230 names and its benchmark-aware risk make it a plausible core international holding rather than a concentrated satellite bet.

This is not investment advice, and Walnut is not an investment adviser. Whether JIRE suits you depends on your goals, time horizon, existing holdings, and how you feel about active management versus a cheaper index fund. Consider how it fits alongside your US and international exposure before deciding.

JIRE trades on US exchanges like any stock, so you can buy it through brokers such as Robinhood, Fidelity, Schwab, or Public. Many of these support fractional shares, letting you invest a fixed dollar amount rather than buying whole shares. You place an order using the JIRE ticker during market hours.

You can also connect your existing broker to Walnut to track JIRE inside a thematic basket alongside the rest of your portfolio. Walnut mirrors your real positions read-only and helps you monitor how the holding aligns with your targets. Trade execution always stays at your broker.

JIRE offers broad developed-market exposure with a modest active tilt at a 0.24% fee, cheaper than most active peers but pricier than plain index funds like IEFA (0.07%) or VEA (0.03%). It works as a core international holding for investors who accept a small active bet in exchange for the chance to edge the EAFE benchmark.

Whether JIRE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, concentration, and what would have to be true for it to outperform from here in is JIRE a buy?

JIRE yields ~2.8% as of mid-2026, paid by passing through the dividends of its underlying holdings. For the payout schedule, history, and how the distributions are taxed, see JIRE dividend: yield and schedule.